secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-10-07T12:00:25+00:00
Accession:  0001628280-26-065291
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Spyre Therapeutics prices $350M stock offering at $85.00/share to fund SPY072 Phase 3 push in hidradenitis suppurativa
--------------------------------------------------------------------------------

- Underwriting agreement dated October 5, 2026 with Jefferies, TD Securities, Leerink Partners and Stifel for 4,117,648 shares at $85.00/share, about $350.0M gross.
- Underwriters granted a 30-day option on up to 617,647 additional shares; offering expected to close on or about October 7, 2026.
- Proceeds fund Gastroenterology, Rheumatology and Dermatology programs, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness.
- Part of the net proceeds will advance SPY072 into late-stage development for hidradenitis suppurativa, plus general infrastructure and potential in-licensing or acquisitions.
- Offering made under shelf registration statement on Form S-3 (File No. 333-297063) effective June 26, 2026; final prospectus supplement dated October 5, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026065291/0001628280-26-065291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026065291/syre-20261005.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-065291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer